3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
39
Brain Neoplasms
17
Astrocytoma
16
Central Nervous System Neoplasms
9
Oligodendroglioma
8
Gliosarcoma
8
Melanoma
7
Glioma
7
Neoplasms
5
Recurrence
4
Neoplasm Metastasis
3
Neuroblastoma
2
Ganglioneuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Choroid Plexus Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdoid Tumor
1
Rare Diseases
1
Optic Nerve Glioma
1
Neurotoxicity Syndromes
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Neuroepithelial
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Melanoma, Cutaneous Malignant
1
Interventions
ponatinib
2
napabucasin
2
Irinotecan
2
Imatinib Mesylate
2
Gemcitabine
2
130-nm albumin-bound paclitaxel
2
pralsetinib
1
pembrolizumab
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
bosutinib
1
Vorinostat
1
Temozolomide
1
Sorafenib
1
Rituximab
1
Pemetrexed
1
Paclitaxel
1
Melphalan
1
Leucovorin
1
Fluorouracil
1
FANG vaccine
1
Etoposide
1
Cytarabine
1
Cisplatin
1
Carmustine
1
Carboplatin
1
Bortezomib
1
Bevacizumab
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Histologic Type
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts